Form 13-F position report

REVANCE THERAPEUTICS INC

Reported by MORGAN STANLEY

RVNC CUSIP 761330109 Manager CIK 0000895421

Reported 682,629 shares, up 179,545 (35.7%) from the prior quarter.

Reported value 165.1%; share count 35.7% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q3 2022
Shares 682,629 Quarter-end amount reported
Reported value $18,430,000 Fair value at quarter end
Consecutive quarters held 35 Through Q3 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 7873000
2021-12-31 6023000
2022-03-31 8133000
2022-06-30 6953000
2022-09-30 18430000
2022-12-31 14745773
2023-03-31 23641368
2023-06-30 16192226
2023-09-30 6907177
2023-12-31 7728599
2024-03-31 5923213
2024-06-30 2511135
2024-09-30 4500393
2024-12-31 2716806
2025-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for REVANCE THERAPEUTICS INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2025 Reduced 0 -893,686 (-100.0%) 0 $0 2025-05-15
Q4 2024 Added 893,686 +26,559 (3.1%) < 0.01% $2,716,806 2025-02-14
Q3 2024 Reduced 867,127 -109,968 (-11.3%) < 0.01% $4,500,393 2024-11-14
Q2 2024 Reduced 977,095 -226,809 (-18.8%) < 0.01% $2,511,135 2024-08-14
Q1 2024 Added 1,203,904 +324,655 (36.9%) < 0.01% $5,923,213 2024-05-15
Q4 2023 Added 879,249 +277,054 (46.0%) < 0.01% $7,728,599 2024-02-13
Q3 2023 Reduced 602,195 -37,561 (-5.9%) < 0.01% $6,907,177 2023-11-15
Q2 2023 Reduced 639,756 -94,220 (-12.8%) < 0.01% $16,192,226 2023-08-14
Q1 2023 Reduced 733,976 -64,820 (-8.1%) < 0.01% $23,641,368 2023-05-15
Q4 2022 Added 798,796 +116,167 (17.0%) < 0.01% $14,745,773 2023-02-14
Q3 2022 Added 682,629 +179,545 (35.7%) < 0.01% $18,430,000 2022-11-14
Q2 2022 Added 503,084 +85,977 (20.6%) < 0.01% $6,953,000 2022-08-15
Q1 2022 Added 417,107 +48,020 (13.0%) < 0.01% $8,133,000 2022-05-13
Q4 2021 Added 369,087 +86,477 (30.6%) < 0.01% $6,023,000 2022-02-14
Q3 2021 Reduced 282,610 -8,091 (-2.8%) < 0.01% $7,873,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

200 managers reported REVANCE THERAPEUTICS INC for Q3 2022.

Managers reporting REVANCE THERAPEUTICS INC in Q3 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Capital World Investors Added 8,048,838 +3,458,838 0.05% $217,319,000 18 qtrs
BlackRock Inc Added 6,131,816 +446,985 < 0.01% $165,559,000 34 qtrs
JPMorgan Chase & Co Reduced 5,450,498 -1,237,427 0.02% $147,163,000 35 qtrs
Polar Capital Holdings Plc Added 4,461,747 +1,344,695 0.77% $120,467,000 8 qtrs
Palo Alto Investors LP Unchanged 4,405,039 0 9.4% $118,936,000 12 qtrs
VANGUARD GROUP INC Added 4,312,896 +609,841 < 0.01% $116,449,000 35 qtrs
FRANKLIN RESOURCES INC Added 2,386,018 +19,651 0.04% $64,422,000 34 qtrs
FMR LLC Added 1,748,990 +534,672 < 0.01% $47,222,730 24 qtrs
BAMCO INC NY Added 1,720,508 +37,500 0.15% $46,454,000 15 qtrs
STATE STREET CORPORATION Reduced 1,616,453 -163,340 < 0.01% $43,644,000 35 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2022
Filed
November 14, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
518,020
Shared
1,476
None
163,133

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.